Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 6,770 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: Prostate Cancer, Prostatic Neoplasms, Neoplasms, Prostate
Interventions: PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uveitis
Interventions: Adalimumab (ADA), Conventional immunosuppression (CON); Biological · Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 13 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 14 more

Conditions: Angina, Unstable, Myocardial Infarction, Ischemic Heart Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 20 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 1,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 640
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thyroid Abnormalities
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 51 Years to 52 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stroke
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Traumatic Stress Disorders, Post-Traumatic Stress Disorders
Interventions: sertraline; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Ipilimumab, Nivolumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 201
States / cities: Auburn, California • Berkeley, California • Cameron Park, California + 140 more

Conditions: Normal Physiology
Interventions: SQUID MEG, OPM MEG; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cocaine-Related Disorders, Drug Administration Schedule, Infusions, Intravenous
Interventions: NS2359; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lennox-Gastaut Syndrome (LGS)
Interventions: Placebo, Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 31
States / cities: Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more

Conditions: Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Leukapheresis; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Wiskott- Aldrich Syndrome, ADA Deficient SCID
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years to 39 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 347
States / cities: Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 215 more

Conditions: Critical Illness
Interventions: Oral Care; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland • Fairfax, Virginia + 1 more

Conditions: Colorectal Neoplasms, Breast Neoplasms
Interventions: Olaparib, Cediranib, Durvalumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: raloxifene, evaluation of cancer risk factors; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 23 Years to 47 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions: Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 151
States / cities: Chula Vista, California • Fremont, California • Fresno, California + 104 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis
Interventions: Romosozumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more

Conditions: Coronary Artery Disease
Interventions: Cardiac CT, Invasive Coronary Angiography; Procedure
Lead sponsor: MDDX LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Subjects, Magnetic Resonance Imaging, Central Nervous System, Volunteer, Neurological Disorder
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 35 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Oxypurinol, Sodium Nitrite; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 40 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers

Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine

Influence of Theta Burst Stimulation and Carbidopa-Levodopa on Motor Performance in Stroke Patients

Evaluation of Stress Disorders

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Characterization of an Optically Pumped Magnetometer (OPM) Magnetoencephalography (MEG) Array

Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

Molecular and Clinical Studies of Primary Immunodeficiency Diseases

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Raloxifene in Preventing Breast Cancer in Premenopausal Women

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis

Transition From Alendronate to Romosozumab (AMG 785)

Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization

Studying Motor Neuron Tests

Nitrite Infusion Studies